DYN · Company research
Dyne Therapeutics, Inc. Common Stock (DYN): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
15records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Why DYN Shares Are Down 10% After-Hours? Day After An FDA Win, Another Announcement Rocks Stock - Stocktwits | Why DYN Shares Are Down 10% After-Hours? Day After An FDA Win, Another Announcement Rocks Stock Stocktwits | View source ↗ | Stocktwits | Oct 9, 2026 | neutral | 0 | 0.6 |
| At $16 a share, director Brian S. Posner buys 2,500 Dyne Therapeutics (DYN) shares. - Stock Titan | At $16 a share, director Brian S. Posner buys 2,500 Dyne Therapeutics (DYN) shares. Stock Titan | View source ↗ | Stock Titan | Oct 6, 2026 | neutral | 0 | 0.6 |
| Dyne Therapeutics (NasdaqGS:DYN) Stock Forecast & Analyst Predictions - Simply Wall Street | Dyne Therapeutics (NasdaqGS:DYN) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Sep 30, 2026 | neutral | 0 | 0.6 |
| After a year, Dyne trial participants showed better walking-test times and muscle strength - Stock Titan | After a year, Dyne trial participants showed better walking-test times and muscle strength Stock Titan | View source ↗ | Stock Titan | Sep 29, 2026 | neutral | 0 | 0.6 |
| Wall Street Weighs Impact On DYN Stock Post Novartis’ Phase 3 Failure — RBC Says These Key Differences Could Lead To Better Outcomes - Stocktwits | Wall Street Weighs Impact On DYN Stock Post Novartis’ Phase 3 Failure — RBC Says These Key Differences Could Lead To Better Outcomes Stocktwits | View source ↗ | Stocktwits | Sep 9, 2026 | neutral | 0 | 0.6 |
| $DYN stock is down 22% today. Here's what we see in our data. - Quiver Quantitative | $DYN stock is down 22% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Sep 8, 2026 | neutral | 0 | 0.6 |
| Dyne Therapeutics Net Loss Widens to $178.6 Million in Q2 2026 - Quiver Quantitative | Dyne Therapeutics Net Loss Widens to $178.6 Million in Q2 2026 Quiver Quantitative | View source ↗ | Quiver Quantitative | Jul 29, 2026 | neutral | 0 | 0.6 |
| Why Dyne Therapeutics (DYN) Stock Is Down Today - Quiver Quantitative | Why Dyne Therapeutics (DYN) Stock Is Down Today Quiver Quantitative | View source ↗ | Quiver Quantitative | Jul 22, 2026 | neutral | 0 | 0.6 |
| Dyne Therapeutics Stock Tumbles After Hours: Here's Why - Benzinga | Dyne Therapeutics Stock Tumbles After Hours: Here's Why Benzinga | View source ↗ | Benzinga | Jul 22, 2026 | neutral | 0 | 0.6 |
| Dyne Therapeutics shares slide after pricing $375 million public offering (NASDAQ:DYN) - Yahoo Finance | Dyne Therapeutics shares slide after pricing $375 million public offering (NASDAQ:DYN) Yahoo Finance | View source ↗ | Yahoo Finance | Jul 22, 2026 | neutral | 0 | 0.6 |
| DYN Stock Rises 19.2% in 3 Months: What's Driving the Rally? - Yahoo Finance | DYN Stock Rises 19.2% in 3 Months: What's Driving the Rally? Yahoo Finance | View source ↗ | Yahoo Finance | Jul 21, 2026 | neutral | 0 | 0.6 |
| Why DYN Shares Are Down 10% After-Hours? Day After An FDA Win, Another Announcement Rocks Stock - TradingView | Why DYN Shares Are Down 10% After-Hours? Day After An FDA Win, Another Announcement Rocks Stock TradingView | View source ↗ | TradingView | Jul 21, 2026 | neutral | 0 | 0.6 |
| DYN Forecast — Price Target — Prediction for 2027 - TradingView | DYN Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 25, 2026 | neutral | 0 | 0.6 |
| DYN Stock Gains As It Gears Up For Accelerated Approval Of DMD Therapy: Wall Street Sees 140% Upside - Stocktwits | DYN Stock Gains As It Gears Up For Accelerated Approval Of DMD Therapy: Wall Street Sees 140% Upside Stocktwits | View source ↗ | Stocktwits | May 20, 2026 | neutral | 0 | 0.6 |
| Dyne Therapeutics, Inc. Common Stock (DYN) Stock Price: Oct 7 Close $15.97 - Gotrade | Dyne Therapeutics, Inc. Common Stock (DYN) Stock Price: Oct 7 Close $15.97 Gotrade | View source ↗ | Gotrade | Jan 13, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.